Unknown

Dataset Information

0

SARS-CoV-2-neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma.

ABSTRACT:

SUBMITTER: Malin JJ 

PROVIDER: S-EPMC8683250 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma.
| S-EPMC8386582 | biostudies-literature
Unknown BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age.
| S-EPMC9533669 | biostudies-literature
Unknown SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
| S-EPMC7646625 | biostudies-literature
Unknown Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
| S-EPMC8386466 | biostudies-literature
Unknown A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.
| S-EPMC8787029 | biostudies-literature
Unknown Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.
| S-EPMC7464057 | biostudies-literature
Unknown Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy.
| S-EPMC8837488 | biostudies-literature
Unknown Neutralizing antibody titres in SARS-CoV-2 infections.
| S-EPMC7782739 | biostudies-literature
Unknown SARS-CoV-2-Induced Remission of Chemotherapy Resistance B-Cell Non-Hodgkin Lymphoma: A Case Report.
| S-EPMC11542925 | biostudies-literature
Unknown Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice.
| S-EPMC9075978 | biostudies-literature